Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

HER2-positive breast cancer, once associated with poor outcomes, now sees improved prognosis due to targeted therapies like Herceptin. Combination therapies and neoadjuvant treatments have enhanced ...

Seagen said that the antibody in its ADC may be superior to trastuzumab, as it has a higher affinity for HER2 and gets into cells more effectively, although that will have to be put to the test in ...

HER2-positive breast cancers can be very aggressive. For several years, the drug Herceptin has been used to treat women with HER2-positive breast cancer that has metastasized or recurred.

Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab ...

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

The antibody-drug conjugate trastuzumab deruxtecan has been approved since January 2021 for pretreated adults with HER2-positive breast cancer that has metastasized or can no longer be operated on.